Onset dynamics of type A botulinum neurotoxin-induced paralysis

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 35, Issue 3, 2008, Pages 251-267

  Lebeda, Frank J ^a   Adler, Michael ^b   Erickson, Keith ^c   Chushak, Yaroslav ^d,e  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

^c UNITED STATES MILITARY ACADEMY   (United States)

^d U S ARMY MEDICAL RESEARCH AND MATERIEL COMMAND   (United States)

^e WRIGHT PATTERSON AIR FORCE BASE   (United States)

Author keywords

Clinical data; In vitro data; In vivo data; Stimulation frequency dependence; Toxicodynamics

Indexed keywords

BOTULINUM TOXIN A; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; ZINC;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CALCULATION; CHOLINERGIC NERVE; CHOLINERGIC TRANSMISSION; CLOSTRIDIUM DIFFICILE; DRUG BINDING; DRUG MECHANISM; ENDOCYTOSIS; ENZYME ACTIVE SITE; FLACCID PARALYSIS; INTERNALIZATION; KINETICS; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MOUSE; NEUROMUSCULAR SYNAPSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN TRANSPORT; REACTION ANALYSIS; SIMULATION; SKELETAL MUSCLE; TIME;

ALGORITHMS; ANIMALS; AREA UNDER CURVE; BOTULINUM TOXIN TYPE A; COMPUTER SIMULATION; MODELS, STATISTICAL; NEUROMUSCULAR AGENTS; NEUROMUSCULAR JUNCTION; PARALYSIS; RATS; RECEPTORS, DRUG; SYNAPTOSOMES;

EID: 47149097982     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-008-9087-3     Document Type: Article

References (42)

1. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, Lillibridge S, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Swerdlow DL, Tonat K (2001) Botulinum toxin as a biological weapon: medical and public health management. JAMA 285: 1059-1070
2. Johnson EA, Bradshaw M (2001) Clostridium botulinum and its neurotoxins: a metabolic and cellular perspective. Toxicon 39: 1703-1722
3. Simpson LL (2004) Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol 44: 167-193
4. Ravichandran E, Gong Y, Al Saleem FH, Ancharski DM, Joshi SG, Simpson LL (2006) An initial assessment of the systemic pharmacokinetics of botulinum toxin. J Pharmacol Exp Ther 318: 1343-1351
5. Adler M, Oyler G, Keller JE, Lebeda FJ (2000) Pharmacological countermeasures for botulinum intoxication. In: Somani SM, Romano JA(eds) Chemical warfare agents: toxicity at low levels. CRC Press, Boca Raton, pp 373-391
6. Millard CB (2005) Medical defense against protein toxin weapons. In: Lindler L, Lebeda FJ, Korch G(eds) Biological weapons defense: principles and mechanisms of infectious diseases and counterbioterrorism. Humana Press Inc, Totowa, pp 255-283
7. Aoki KR (2004) Botulinum toxin: a successful therapeutic protein. Curr Med Chem 11: 3085-3092
8. Public Law Project BioShield Act of 2004, 108-276, 118 Stat 835. Government Printing Office, Washington, DC (2004)
9. US Department of Health and Human Services, Project BioShield: Medical countermeasures for botulism (2007) http://www.hhs.gov/aspr/barda/mcm/botulism. html. Accessed 14 March 2008
10. US Department of Health and Human Services, HHS awards BioShield contract for botulism antitoxin (2006) http://www.hhs.gov/news/press/2006pres/20060601. html. Accessed 14 March 2008
11. Marks JD (2004) Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization. Mov Disord 19(8): S101-108
12. Verderio C, Rossetto O, Grumelli C, Frassoni C, Montecucco C, Matteoli M (2006) Entering neurons: botulinum toxins and synaptic vesicle recycling. EMBO Reports 7: 995-999
13. Lebeda FJ, Singh BR (1999) Membrane channel activity and translocation of tetanus and botulinum neurotoxins. J Toxicol Toxin Rev 18: 45-76
14. Schiavo G, Matteoli M, Montecucco C (2000) Neurotoxins affecting neuroexocytosis. Physiol Rev 80: 717-766
15. Simpson LL (1980) Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther 212: 16-21
16. Aoki KR (2002) Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety. Toxicon 40: 923-928
17. Keller JE (2006) Recovery from botulinum neurotoxin poisoning in vivo. Neuroscience 139: 629-637
18. Dressler D, Adib Saberi F (2005) Botulinum toxin: mechanisms of action. Eur Neurol 53: 3-9
19. 125I-labelled botulinum neurotoxin at murine neuromuscular junction and its binding to rat brain synaptosomes. Toxicon 20: 141-148
20. Segel IH (1975) Enzyme kinetics. Wiley-Interscience, New York
21. Adler M, Albuquerque EX, Lebeda FJ (1978) Kinetic analysis of end plate currents altered by atropine and scopolamine. Mol Pharmacol 14: 514-529
22. Hablitz JJ, Lebeda FJ (1985) Role of uptake in gamma-aminobutyric acid (GABA)-mediated responses in guinea pig hippocampal neurons. Cell Mol Neurobiol 5: 353-371
23. Simpson LL (1974) Studies on the binding of botulinum toxin type A to the rat phrenic nerve-hemidiaphragm preparation. Neuropharmacology 13: 683-691
24. Dressler D (2000) Botulinum toxin therapy. Georg Thieme Verlag, Stutgard
25. Sauro HM, Hucka M, Finney A, Wellock C, Bolouri H, Doyle J, Kitano H. (2003) Next generation simulation tools: the systems biology workbench and BioSPICE integration. OMICS 7: 355-372
26. Daniels-Holgate PU, Dolly JO (1996) Productive and non-productive binding of botulinum neurotoxin A to motor nerve endings are distinguished by its heavy chain. J Neurosci Res 44: 263-271
27. Hiromi K (1979) Kinetics of fast enzyme reactions. John Wiley and Sons, New York
28. De Lean A, Rodbard D (1979) Kinetics of cooperative binding. In: O'Brien RD (ed) The receptors: a comprehensive treatise. Plenum Press, New York, pp 143-192
29. Chertow DS, Tan ET, Maslanka SE, Schulte J, Bresnitz EA, Weisman RS, Bernstein J, Marcus SM, Kumar S, Malecki J, Sobel J, Braden CR (2006) Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. JAMA 296: 2476-2479
30. Yowler BC, Schengrund CL (2004) Botulinum neurotoxin A changes conformation upon binding to ganglioside GT1b. Biochemistry 43: 9725-9731
31. Rummel A, Mahrhold S, Bigalke H, Binz T (2004) The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction. Mol Microbiol 51: 631-643
32. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, Chapman ER (2006) SV2 is the protein receptor for botulinum neurotoxin A. Science 312: 592-596
33. Mahrhold S, Rummel A, Bigalke H, Davletov B, Binz T (2006) The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett 580: 2011-2014
34. Wyman J, Gill SJ (1990) Binding and linkage: functional chemistry of biological macromolecules. University Science Books, Mill Valley
35. Adler M, Scovill J, Parker G, Lebeda FJ, Piotrowski J, Deshpande SS (1995) Antagonism of botulinum toxin-induced muscle weakness by 3,4-diaminopyridine in rat phrenic nerve-hemidiaphragm preparations. Toxicon 33: 527-537
36. Koriazova LK, Montal M (2003) Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat Struct Biol 10: 13-18
37. Schmidt JJ, Bostian KA (1997) Endoproteinase activity of type A botulinum neurotoxin: substrate requirements and activation by serum albumin. J Protein Chem 16: 19-26
38. Jurasinski CV, Lieth E, Dang Do AN, Schengrund CL (2001) Correlation of cleavage of SNAP-25 with muscle function in a rat model of Botulinum neurotoxin type A induced paralysis. Toxicon 39: 1309-1315
39. Kalandakanond S, Coffield JA (2001) Cleavage of SNAP-25 by botulinum toxin type A requires receptor-mediated endocytosis, pH-dependent translocation, and zinc. J Pharmacol Exp Ther 296: 980-986
40. Meunier FA, Lisk G, Sesardic D, Dolly JO (2003) Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: the extent and duration are dictated by the sites of SNAP-25 truncation. Mol Cell Neurosci 22: 454-466
41. Kongsaengdao S, Samintarapanya K, Rusmeechan S, Wongsa A, Pothirat C, Permpikul C, Pongpakdee S, Puavilai W, Kateruttanakul P, Phengtham U, Panjapornpon K, Janma J, Piyavechviratana K, Sithinamsuwan P, Deesomchok A, Tongyoo S, Vilaichone W, Boonyapisit K, Mayotarn S, Piya-Isragul B, Rattanaphon A, Intalapaporn P, Dusitanond P, Harnsomburana P, Laowittawas W, Chairangsaris P, Suwantamee J, Wongmek W, Ratanarat R, Poompichate A, Panyadilok H, Sutcharitchan N, Chuesuwan A, Oranrigsupau P, Sutthapas C, Tanprawate S, Lorsuwansiri J, Phattana N (2006) An outbreak of botulism in Thailand: clinical manifestations and management of severe respiratory failure. Clin Infect Dis 43: 1247-1256
42. Jones JA, Salmon JE, Djuretic T, Nichols G, George RC, Gill ON, Brazier JS, Brett MM, Duerden BI, Fry NK, Hall V, Hope V, Lieftucht A, McLauchlin J, Pitcher DG, Weild A (2002) An outbreak of serious illness and death among injecting drug users in England during 2000. J Med Microbiol 51: 978-984